Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
gptkb:drug |
| gptkbp:approvalYear |
2011
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
S01LA05
|
| gptkbp:brand |
gptkb:Eylea
|
| gptkbp:developedBy |
gptkb:Bayer
gptkb:Regeneron_Pharmaceuticals |
| gptkbp:form |
solution for injection
|
| gptkbp:genericName |
gptkb:aflibercept
|
| https://www.w3.org/2000/01/rdf-schema#label |
VEGF Trap-Eye
|
| gptkbp:indication |
gptkb:neovascular_age-related_macular_degeneration
macular edema following central retinal vein occlusion |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
VEGF inhibitor
|
| gptkbp:routeOfAdministration |
intravitreal injection
|
| gptkbp:target |
gptkb:VEGF-A
gptkb:VEGF-B gptkb:placental_growth_factor |
| gptkbp:usedFor |
gptkb:diabetic_macular_edema
myopic choroidal neovascularization |
| gptkbp:bfsParent |
gptkb:somavaratan
|
| gptkbp:bfsLayer |
8
|